In patients diagnosed with severe COVID-19, increased levels of pro-inflammatory cytokines, (e.g., soluble IL-2R, IL-6, IL-8, and TNF-α) have been observed, with these cytokines disrupting endothelial cells antithrombotic and anti-inflammatory functions, leading to coagulation dysregulation, complement and platelet activation, and leukocyte recruitment in the microvasculature [63, 64]. This evidence concerns the gene IL6 and COVID-19.